Although conventional meta-analyses of the efficacy of DD in HSP treatment exist [15-17], they suffer from limitations such as incomplete literature retrieval, for instance, a lack of review of references in the included articles and previous reviews in the field; and inadequate analysis of outcome measures, for example, a failure to analyze IgA levels, recurrence rates, incidence of adverse reactions, and so forth. Here, CD79A is linked to hereditary spastic paraplegia.